# A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

Source: https://onco.cc/trials/nct06644768/  
OnCo record `nct06644768` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Daiichi Sankyo, active and no longer recruiting.

## Summary

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations is a phase 1/2 interventional study registered as NCT06644768 by Daiichi Sankyo, with 137 participants planned, started 2024-10-30 and due to reach its primary completion in 2028-03-30. Interventions recorded: valemetostat tosylate, pembrolizumab. Conditions listed: Non-small Cell Lung Cancer, Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06644768
- Phase: 1/2
- Setting: A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial Of Valemetostat Tosylate Plus Pembrolizumab Vs Pembrolizumab Alone in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 With Tumor Proportion Score ≥50% Without Actionable Genomic Alterations
- Sponsor: Daiichi Sankyo
- Enrolled: 137

## Sources

- ClinicalTrials.gov NCT06644768: https://clinicaltrials.gov/study/NCT06644768

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct06644768.json